drugset / Trial / NCT00146588
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
Completed
55 enrolled
Craig A. Bunnell, MD, MPH
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabDana-Farber Cancer Institute · collabMassachusetts General Hospital · collabPharmacia · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Timeline
- Start
- 2002-04
- Primary completion
- 2004-12
- Completion
- 2004-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Epirubicin | Small molecule | — | Intravenous |